Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Amneal Pharmaceuticals's annualizedNet Income for the quarter that ended in Jun. 2026 was €200 Mil. Amneal Pharmaceuticals's average total tangible assets for the quarter that ended in Jun. 2026 was €2,169 Mil. Therefore, Amneal Pharmaceuticals's annualized Return-on-Tangible-Asset for the quarter that ended in Jun. 2026 was 9.23%.
The historical rank and industry rank for Amneal Pharmaceuticals's Return-on-Tangible-Asset or its related term are showing as below:
STU:2DT'
s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: -17.5 Med: -4.11 Max: 13.19
Current: 6.49
During the past 10 years, Amneal Pharmaceuticals's highest Return-on-Tangible-Asset was 13.19%. The lowest was -17.50%. And the median was -4.11%.
STU:2DT's Return-on-Tangible-Asset is ranked better than 60.26% of 1009
companies
in the Drug Manufacturers industry
Industry Median: 3.13
vs STU:2DT: 6.49
Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.
Be Aware
Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the companys earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a companys tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.
Amneal Pharmaceuticals Return-on-Tangible-Asset Related Terms
Amneal Pharmaceuticals Return-on-Tangible-Asset Historical Data
* Premium members only.
The historical data trend for Amneal Pharmaceuticals's Return-on-Tangible-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:2DT vs HIMS, KNSA, INDV: Return-on-Tangible-Asset Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Amneal Pharmaceuticals's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Amneal Pharmaceuticals Return-on-Tangible-Asset vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Amneal Pharmaceuticals's Return-on-Tangible-Asset distribution charts can be found below:
* The bar in red indicates where Amneal Pharmaceuticals's Return-on-Tangible-Asset falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Jun. 2026) net income data.
What does a Return-on-Tangible-Asset of 9.23% mean?
Amneal Pharmaceuticals (STU:2DT) has a Return-on-Tangible-Asset of 9.23% as of Jun. 2026. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Amneal Pharmaceuticals and its competitors. According to the industry distribution chart, Amneal Pharmaceuticals ranks #401 out of 1009 companies in the Drug Manufacturers industry, placing it in the top 39.7%.
Is Amneal Pharmaceuticals' Return-on-Tangible-Asset too high?
Amneal Pharmaceuticals' current Return-on-Tangible-Asset is 9.23%. The Drug Manufacturers industry median Return-on-Tangible-Asset is 3.13. Amneal Pharmaceuticals' value of 9.23% is 194.9% above this industry median. Based on the distribution chart, Amneal Pharmaceuticals ranks #401 out of 1009 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Amneal Pharmaceuticals has a GF Score™ of 63/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Amneal Pharmaceuticals' Return-on-Tangible-Asset compare to HIMS and KNSA?
According to the Drug Manufacturers industry distribution chart, Amneal Pharmaceuticals ranks #401 out of 1009 companies for Return-on-Tangible-Asset. This puts Amneal Pharmaceuticals in the upper half of its industry. The industry median Return-on-Tangible-Asset is 3.13. Amneal Pharmaceuticals' value of 9.23% is 194.9% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Asset for a Drug Manufacturers company?
The median Return-on-Tangible-Asset among Drug Manufacturers companies is 3.13, based on 1,009 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Asset significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Amneal Pharmaceuticals's current Return-on-Tangible-Asset of 9.23% is 194.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Asset mean?
A high Return-on-Tangible-Asset can signal that a stock is expensive relative to its fundamentals. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Amneal Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median Return-on-Tangible-Asset is 3.13 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Amneal Pharmaceuticals's current Return-on-Tangible-Asset is 9.23%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Amneal Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Amneal Pharmaceuticals (STU:2DT) is currently considered Significantly Overvalued. The stock's GF Value™ is €7.83, compared to a current price of €17.80 — trading 127.3% above its estimated fair value. The current Return-on-Tangible-Asset is 9.23% and 194.9% above the Drug Manufacturers industry median of 3.13. Amneal Pharmaceuticals' overall GF Score™ is 63/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Asset calculated?
Return-on-Tangible-Asset is calculated from a company's financial statements. For Amneal Pharmaceuticals (STU:2DT), the current Return-on-Tangible-Asset is 9.23% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Amneal Pharmaceuticals (STU:2DT) Overvalued in 2026?
Based on GuruFocus' analysis, Amneal Pharmaceuticals stock appears to be overvalued.
The current stock price of €17.80 is trading 127.3% above its estimated GF Value™ of €7.83.
GuruFocus considers Amneal Pharmaceuticals to be Significantly Overvalued.
Key valuation signals for STU:2DT:
Return-on-Tangible-Asset: 9.23%
GF Value™: €7.83 vs. price of €17.80 (127.3% above fair value)
Industry Position: 194.9% above the Drug Manufacturers median (#401 of 1009)
No single metric tells the full story. See the STU:2DT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Amneal Pharmaceuticals Inc is a pharmaceutical company operating in the U.S., India, and Ireland. With three reportable segments; Affordable Medicines, Specialty, and AvKARE. It develops, manufactures, and distributes a diverse portfolio of essential medicines. The Affordable Medicines segment, which derives maximum revenue, focuses on a wide range of dosage forms and delivery systems, contributing significantly to revenues. The Specialty segment promotes proprietary branded pharmaceuticals, particularly targeting the central nervous system and endocrine disorders. The AvKARE segment provides pharmaceuticals and medical products to governmental agencies, specializing in re-packaging and wholesale distribution, with a focus on offering consistent care and pricing to qualified entities.
63GF Score
Get the complete analysis for STU:2DT
Return-on-Tangible-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:2DT has been successfully added to your 
